Advancements in immune tolerance

Advanced Drug Delivery Reviews

Volumn 60, Issue 2, 2008, Pages 91-105

  Pan, Ping Ying ^a   Ozao, Junko ^a   Zhou, Zuping ^a   Chen, Shu Hsia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune; Cancer immune therapy; Dendritic cells; GVHD; Immune tolerance; MDSC; Treg

Indexed keywords

CELL CULTURE; DISEASES; IMMUNIZATION; MATHEMATICAL MODELS;

CANCER IMMUNE THERAPY; DENDRITIC CELLS; GVHD; IMMUNE TOLERANCE;

ONCOLOGY;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL POPULATION; CELL THERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS;

EID: 36849088028     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.025     Document Type: Review

References (230)

1. Kappler J.W., Roehm N., and Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 49 2 (1987) 273-280
2. + thymocytes. Nature 333 6175 (1988) 742-746
3. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat. Rev. Immunol. 3 5 (2003) 383-391
4. Starr T.K., Jameson S.C., and Hogquist K.A. Positive and negative selection of T cells. Annu. Rev. Immunol. 21 (2003) 139-176
5. Arnold B., Schonrich G., and Hammerling G.J. Multiple levels of peripheral tolerance. Immunol. Today 14 1 (1993) 12-14
6. Van Parijs L., and Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280 5361 (1998) 243-248
7. Walker L.S., and Abbas A.K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2 1 (2002) 11-19
8. Guerder S., Picarella D.E., Linsley P.S., and Flavell R.A. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. U S A 91 11 (1994) 5138-5142
9. Weigle W.O. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv. Immunol. 30 (1980) 159-273
10. Maloy K.J., and Powrie F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2 9 (2001) 816-822
11. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 5 (2000) 455-458
12. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
13. *. Annu. Rev. Immunol. 18 (2000) 423-449
14. Tang Q., and Bluestone J.A. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?. Nat. Immunol. 7 6 (2006) 551-553
15. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25 (2007) 267-296
16. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., Angeli V., Li Y., Boros P., Ding Y., Jessberger R., Trinchieri G., Lira S.A., Randolph G.J., and Bromberg J.S. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7 6 (2006) 652-662
17. Munn D.H., and Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213 (2006) 146-158
18. Mahnke K., Johnson T.S., Ring S., and Enk A.H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci. 46 3 (2007) 159-167
19. +T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 12 (2005) 7898-7904
20. Kim R., Emi M., and Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119 2 (2006) 254-264
21. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 2 (2006) 1123-1131
22. Vlad G., Cortesini R., and Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol. 174 10 (2005) 5907-5914
23. + Tregs and immune control. J. Clin. Invest. 114 9 (2004) 1209-1217
24. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 3 (1995) 1151-1164
25. + T regulatory cells. Nat. Immunol. 4 4 (2003) 337-342
26. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 5609 (2003) 1057-1061
27. + regulatory T cells. Nat. Immunol. 4 4 (2003) 330-336
28. Pennington D.J., Silva-Santos B., Silberzahn T., Escorcio-Correia M., Woodward M.J., Roberts S.J., Smith A.L., Dyson P.J., and Hayday A.C. Early events in the thymus affect the balance of effector and regulatory T cells. Nature 444 7122 (2006) 1073-1077
29. Lin W., Haribhai D., Relland L.M., Truong N., Carlson M.R., Williams C.B., and Chatila T.A. Regulatory T cell development in the absence of functional Foxp3. Nat. Immunol. 8 4 (2007) 359-368
30. Fontenot J.D., Dooley J.L., Farr A.G., and Rudensky A.Y. Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. 202 7 (2005) 901-906
31. + regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc. Natl. Acad. Sci. U S A 103 22 (2006) 8453-8458
32. + medullary thymic epithelial cells. Nat. Immunol. 8 4 (2007) 351-358
33. +CD25 - precursors. Am. J. Transplant. 4 10 (2004) 1614-1627
34. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 12 (2003) 1875-1886
35. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101 12 (2003) 4862-4869
36. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., and von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6 12 (2005) 1219-1227
37. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., de Waal-Malefyt R., Coffman R.L., Hawrylowicz C.M., and O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195 5 (2002) 603-616
38. Levings M.K., Sangregorio R., Galbiati F., Squadrone S., de Waal Malefyt R., and Roncarolo M.G. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166 9 (2001) 5530-5539
39. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 6652 (1997) 737-742
40. Carrier Y., Yuan J., Kuchroo V.K., and Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J. Immunol. 178 1 (2007) 179-185
41. Carrier Y., Yuan J., Kuchroo V.K., and Weiner H.L. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J. Immunol. 178 1 (2007) 172-178
42. Inobe J., Slavin A.J., Komagata Y., Chen Y., Liu L., and Weiner H.L. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28 9 (1998) 2780-2790
43. + T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J. Immunol. 160 12 (1998) 5719-5728
44. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182 (2001) 207-214
45. Weiner H.L. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat. Immunol. 2 8 (2001) 671-672
46. + regulatory T cells in human ovarian carcinoma. Cancer Res. 65 12 (2005) 5020-5026
47. + regulatory T cells in the maintenance of T cell homeostasis. J. Exp. Med. 200 9 (2004) 1123-1134
48. + T cells with a regulatory phenotype and function. Eur. J. Immunol. 35 10 (2005) 2896-2908
49. Hahn B.H., Singh R.P., La Cava A., and Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol. 175 11 (2005) 7728-7737
50. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195 6 (2002) 695-704
51. + regulatory thymocytes. Blood 102 12 (2003) 4107-4114
52. + T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J. Immunol. 175 1 (2005) 246-253
53. Annunziato F., Cosmi L., Liotta F., Lazzeri E., Manetti R., Vanini V., Romagnani P., Maggi E., and Romagnani S. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J. Exp. Med. 196 3 (2002) 379-387
54. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9 9 (2003) 1144-1150
55. Godfrey W.R., Ge Y.G., Spoden D.J., Levine B.L., June C.H., Blazar B.R., and Porter S.B. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104 2 (2004) 453-461
56. + T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood 105 4 (2005) 1828-1836
57. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., Morris P.J., Powrie F., and Wood K.J. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166 6 (2001) 3789-3796
58. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., and Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104 3 (2004) 895-903
59. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., and Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193 11 (2001) 1285-1294
60. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168 3 (2002) 1080-1086
61. + T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196 10 (2002) 1335-1346
62. Nakamura K., Kitani A., and Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194 5 (2001) 629-644
63. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192 2 (2000) 295-302
64. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., and Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192 2 (2000) 303-310
65. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188 2 (1998) 287-296
66. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest. 112 11 (2003) 1688-1696
67. Waldmann H., Graca L., Cobbold S., Adams E., Tone M., and Tone Y. Regulatory T cells and organ transplantation. Semin. Immunol. 16 2 (2004) 119-126
68. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., and Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 6 (2001) 823-832
69. Steitz J., Bruck J., Lenz J., Knop J., and Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61 24 (2001) 8643-8646
70. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 10 (1999) 5211-5218
71. Onizuka S., Tawara I., Shimizu J., Sakaguchi S., Fujita T., and Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59 13 (1999) 3128-3133
72. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32 11 (2002) 3267-3275
73. Annacker O., Burlen-Defranoux O., Pimenta-Araujo R., Cumano A., and Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J. Immunol. 164 7 (2000) 3573-3580
74. Asseman C., Mauze S., Leach M.W., Coffman R.L., and Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190 7 (1999) 995-1004
75. - cells and CD4(+)CD8(-) thymocytes. J. Exp. Med. 189 2 (1999) 279-288
76. + T cells. J. Exp. Med. 183 6 (1996) 2669-2674
77. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10 12 (1998) 1969-1980
78. + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30 6 (2000) 1538-1543
79. Lu L.F., Lind E.F., Gondek D.C., Bennett K.A., Gleeson M.W., Pino-Lagos K., Scott Z.A., Coyle A.J., Reed J.L., Van Snick J., Strom T.B., Zheng X.X., and Noelle R.J. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442 7106 (2006) 997-1002
80. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., and Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 1 (2001) 678-689
81. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., and Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67 1 (2007) 425 author reply 426
82. + T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175 7 (2005) 4583-4592
83. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165 2 (2000) 779-785
84. Melani C., Chiodoni C., Forni G., and Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102 6 (2003) 2138-2145
85. Sinha P., Clements V.K., and Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 2 (2005) 636-645
86. Van Ginderachter J.A., Movahedi K., Hassanzadeh Ghassabeh G., Meerschaut S., Beschin A., Raes G., and De Baetselier P. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211 6-8 (2006) 487-501
87. Young M.R., Newby M., and Wepsic H.T. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47 1 (1987) 100-105
88. + cells within human head and neck squamous cell carcinomas. J. Immunol. 159 2 (1997) 990-996
89. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., and Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65 8 (2005) 3044-3048
90. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., Musiani P., Zanovello P., and Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. U S A 102 11 (2005) 4185-4190
91. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., Zanovello P., and Segal D.M. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168 2 (2002) 689-695
92. + T cells. J. Clin. Invest. 116 10 (2006) 2777-2790
93. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., and Ochoa A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 16 (2004) 5839-5849
94. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., Gilbert J., and Ochoa A.C. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202 7 (2005) 931-939
95. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., Segal D.M., Staib C., Lowel M., Sutter G., Colombo M.P., and Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170 1 (2003) 270-278
96. Kusmartsev S., and Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74 2 (2003) 186-196
97. Schmielau J., and Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61 12 (2001) 4756-4760
98. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D.L., Schneck J., and Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8(+) T cell tolerance in cancer. Nat. Med. 13 7 (2007) 828-835
99. Sica A., Schioppa T., Mantovani A., and Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42 6 (2006) 717-727
100. Bingle L., Brown N.J., and Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196 3 (2002) 254-265
101. Kusmartsev S., and Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174 8 (2005) 4880-4891
102. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., and Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179 2 (2007) 977-983
103. Koseki H., Imai K., Ichikawa T., Hayata I., and Taniguchi M. Predominant use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. Int. Immunol. 1 6 (1989) 557-564
104. Fowlkes B.J., Kruisbeek A.M., Ton-That H., Weston M.A., Coligan J.E., Schwartz R.H., and Pardoll D.M. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 329 6136 (1987) 251-254
105. + thymocytes selected by MHC class I molecules. Science 263 5154 (1994) 1774-1778
106. Vincent M.S., Gumperz J.E., and Brenner M.B. Understanding the function of CD1-restricted T cells. Nat. Immunol. 4 6 (2003) 517-523
107. Terabe M., and Berzofsky J.A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16 2 (2004) 157-162
108. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21 (2003) 483-513
109. Kronenberg M., and Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2 8 (2002) 557-568
110. Bendelac A., Rivera M.N., Park S.H., and Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15 (1997) 535-562
111. Makino Y., Kanno R., Ito T., Higashino K., and Taniguchi M. Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int. Immunol. 7 7 (1995) 1157-1161
112. - T cells in mice and humans. J. Exp. Med. 180 3 (1994) 1097-1106
113. Imai K., Kanno M., Kimoto H., Shigemoto K., Yamamoto S., and Taniguchi M. Sequence and expression of transcripts of the T-cell antigen receptor alpha-chain gene in a functional, antigen-specific suppressor-T-cell hybridoma. Proc. Natl. Acad. Sci. U. S. A. 83 22 (1986) 8708-8712
114. Seino K.I., Fukao K., Muramoto K., Yanagisawa K., Takada Y., Kakuta S., Iwakura Y., Van Kaer L., Takeda K., Nakayama T., Taniguchi M., Bashuda H., Yagita H., and Okumura K. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc. Natl. Acad. Sci. U. S. A. 98 5 (2001) 2577-2581
115. Lan F., Zeng D., Higuchi M., Huie P., Higgins J.P., and Strober S. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J. Immunol. 167 4 (2001) 2087-2096
116. Lan F., Zeng D., Higuchi M., Higgins J.P., and Strober S. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant. 9 6 (2003) 355-363
117. Ikehara Y., Yasunami Y., Kodama S., Maki T., Nakano M., Nakayama T., Taniguchi M., and Ikeda S. CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J. Clin. Invest. 105 12 (2000) 1761-1767
118. Higuchi M., Zeng D., Shizuru J., Gworek J., Dejbakhsh-Jones S., Taniguchi M., and Strober S. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. J. Immunol. 169 10 (2002) 5564-5570
119. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., Joyce S., Sriram S., Koezuka Y., and Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194 12 (2001) 1801-1811
120. Miyamoto K., Miyake S., and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 6855 (2001) 531-534
121. Mars L.T., Laloux V., Goude K., Desbois S., Saoudi A., Van Kaer L., Lassmann H., Herbelin A., Lehuen A., and Liblau R.S. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168 12 (2002) 6007-6011
122. Laloux V., Beaudoin L., Jeske D., Carnaud C., and Lehuen A. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J. Immunol. 166 6 (2001) 3749-3756
123. Jahng A.W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., Koezuka Y., and Kumar V. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194 12 (2001) 1789-1799
124. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187 7 (1998) 1047-1056
125. Furlan R., Bergami A., Cantarella D., Brambilla E., Taniguchi M., Dellabona P., Casorati G., and Martino G. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33 7 (2003) 1830-1838
126. Berkers C.R., and Ovaa H. Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci. 26 5 (2005) 252-257
127. - T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 46 4 (1997) 572-582
128. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., and Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 6 (2000) 515-520
129. Ostrand-Rosenberg S., Clements V.K., Terabe M., Park J.M., Berzofsky J.A., and Dissanayake S.K. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J. Immunol. 169 10 (2002) 5796-5804
130. + T cells to the spleen during the generation of regulatory T cells in tolerance. J. Immunol. 169 1 (2002) 31-38
131. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., and Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 11 (2003) 1741-1752
132. Vremec D., Pooley J., Hochrein H., Wu L., and Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J. Immunol. 164 6 (2000) 2978-2986
133. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2 3 (2002) 151-161
134. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., Gunther G., Johnston I., Lanzavecchia A., Nagasaka T., Okada T., Vermi W., Winkels G., Yamamoto T., Zysk M., Yamaguchi Y., and Schmitz J. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 194 12 (2001) 1823-1834
135. Dzionek A., Inagaki Y., Okawa K., Nagafune J., Rock J., Sohma Y., Winkels G., Zysk M., Yamaguchi Y., and Schmitz J. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum. Immunol. 63 12 (2002) 1133-1148
136. Asselin-Paturel C., Boonstra A., Dalod M., Durand I., Yessaad N., Dezutter-Dambuyant C., Vicari A., O'Garra A., Biron C., Briere F., and Trinchieri G. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2 12 (2001) 1144-1150
137. Belz G.T., Behrens G.M., Smith C.M., Miller J.F., Jones C., Lejon K., Fathman C.G., Mueller S.N., Shortman K., Carbone F.R., and Heath W.R. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196 8 (2002) 1099-1104
138. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
139. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22 (2004) 307-328
140. Swanson K.A., Zheng Y., Heidler K.M., Mizobuchi T., and Wilkes D.S. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell. Mol. Biol. 30 3 (2004) 311-318
141. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., and Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 5380 (1998) 1191-1193
142. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., and Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 3 (2005) 312-319
143. Mellor A.L., Sivakumar J., Chandler P., Smith K., Molina H., Mao D., and Munn D.H. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat. Immunol. 2 1 (2001) 64-68
144. Kwidzinski E., Bunse J., Aktas O., Richter D., Mutlu L., Zipp F., Nitsch R., and Bechmann I. Indoleamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J. 19 10 (2005) 1347-1349
145. Hayashi T., Beck L., Rossetto C., Gong X., Takikawa O., Takabayashi K., Broide D.H., Carson D.A., and Raz E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114 2 (2004) 270-279
146. Gurtner G.J., Newberry R.D., Schloemann S.R., McDonald K.G., and Stenson W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterol. 125 6 (2003) 1762-1773
147. + T cells induced by TCR triggering or homeostatic cytokines. Eur. J. Immunol. 36 2 (2006) 296-304
148. Terness P., Bauer T.M., Rose L., Dufter C., Watzlik A., Simon H., and Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196 4 (2002) 447-457
149. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff Jr. C.L., and Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 5588 (2002) 1867-1870
150. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., and Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196 4 (2002) 459-468
151. Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A., Fioretti M.C., and Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9 10 (2002) 1069-1077
152. + regulatory T cells in human thymus. Nature 436 7054 (2005) 1181-1185
153. + regulatory T cells by inhibition of APC proteosome function. J. Immunol. 174 5 (2005) 2787-2795
154. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192 9 (2000) 1213-1222
155. + regulatory T cells via a TGF-{beta}- and retinoic acid-dependent mechanism. J. Exp. Med. (2007)
156. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., and Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. (2007)
157. Steinbrink K., Wolfl M., Jonuleit H., Knop J., and Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159 10 (1997) 4772-4780
158. Sato K., Yamashita N., Yamashita N., Baba M., and Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18 3 (2003) 367-379
159. Morelli A.E., and Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 7 8 (2007) 610-621
160. van Duivenvoorde L.M., Han W.G., Bakker A.M., Louis-Plence P., Charbonnier L.M., Apparailly F., van der Voort E.I., Jorgensen C., Huizinga T.W., and Toes R.E. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J. Immunol. 179 3 (2007) 1506-1515
161. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., Ugel S., Peranzoni E., Mandruzzato S., and Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol. Invest. 35 3-4 (2006) 327-357
162. Ganss R., and Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58 20 (1998) 4673-4681
163. Fricke I., and Gabrilovich D.I. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol. Invest. 35 3-4 (2006) 459-483
164. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25 2 (2006) 195-201
165. Mills K.H., and McGuirk P. Antigen-specific regulatory T cells-their induction and role in infection. Semin. Immunol. 16 2 (2004) 107-117
166. Vigouroux S., Yvon E., Biagi E., and Brenner M.K. Antigen-induced regulatory T cells. Blood 104 1 (2004) 26-33
167. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120 12 (2007) 2723-2733
168. Litzinger M.T., Fernando R., Curiel T.J., Grosenbach D.W., Schlom J., and Palena C. The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007)
169. + regulatory T cell function. Science 309 5739 (2005) 1380-1384
170. + cells. J. Immunol. 161 10 (1998) 5313-5320
171. Dirkx A.E., Oude Egbrink M.G., Wagstaff J., and Griffioen A.W. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80 6 (2006) 1183-1196
172. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 4 (2004) 409-421
173. Pekarek L.A., Starr B.A., Toledano A.Y., and Schreiber H. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181 1 (1995) 435-440
174. Seung L.P., Rowley D.A., Dubey P., and Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. U. S. A. 92 14 (1995) 6254-6258
175. Rubin B.P., Heinrich M.C., and Corless C.L. Gastrointestinal stromal tumour. Lancet 369 9574 (2007) 1731-1741
176. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 6 Suppl 1 (2006) S30-S34
177. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., and Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203 12 (2006) 2691-2702
178. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., and Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96 12 (2000) 3838-3846
179. + cells in the development of antitumor immunity. Cancer Res. 64 3 (2004) 1130-1139
180. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., and Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 15 (2003) 4441-4449
181. Young M.R., Young M.E., and Wright M.A. Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity. Int. J. Cancer 46 2 (1990) 245-250
182. Alard P., Clark S.L., and Kosiewicz M.M. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta. Eur. J. Immunol. 34 4 (2004) 1021-1030
183. Steinbrink K., Jonuleit H., Muller G., Schuler G., Knop J., and Enk A.H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 93 5 (1999) 1634-1642
184. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.P., and Plumas J. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176 1 (2006) 248-255
185. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., and Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9 10 (2003) 1269-1274
186. Mellor A.L., Chandler P., Baban B., Hansen A.M., Marshall B., Pihkala J., Waldmann H., Cobbold S., Adams E., and Munn D.H. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16 10 (2004) 1391-1401
187. Muller A.J., Malachowski W.P., and Prendergast G.C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets 9 4 (2005) 831-849
188. + T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178 11 (2007) 6840-6848
189. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J.A., Herold K.C., and von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116 5 (2006) 1371-1381
190. You S., Leforban B., Garcia C., Bach J.F., Bluestone J.A., and Chatenoud L. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl. Acad. Sci. U. S. A. 104 15 (2007) 6335-6340
191. Chatenoud L., and Bluestone J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7 8 (2007) 622-632
192. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., Clark M., and Waldmann H. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol. 23 2 (1993) 403-411
193. Xu D., Alegre M.L., Varga S.S., Rothermel A.L., Collins A.M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P.W., Bluestone J.A., Jolliffe L.K., and Zivin R.A. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 200 1 (2000) 16-26
194. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., and Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 22 (2002) 1692-1698
195. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., and Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 25 (2005) 2598-2608
196. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104 12 (2004) 3804-3812
197. + Treg cells. Exp. Hematol. 34 1 (2006) 66-71
198. Bluestone J.A., Thomson A.W., Shevach E.M., and Weiner H.L. What does the future hold for cell-based tolerogenic therapy?. Nat. Rev. Immunol. 7 8 (2007) 650-654
199. MacDonald K.P., Rowe V., Clouston A.D., Welply J.K., Kuns R.D., Ferrara J.L., Thomas R., and Hill G.R. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J. Immunol. 174 4 (2005) 1841-1850
200. Vasconcelos Z.F., Dos Santos B.M., Farache J., Palmeira T.S., Areal R.B., Cunha J.M., Barcinski M.A., and Bonomo A. G-CSF-treated granulocytes inhibit acute graft-versus-host disease. Blood 107 5 (2006) 2192-2199
201. Lutz M.B., Suri R.M., Niimi M., Ogilvie A.L., Kukutsch N.A., Rossner S., Schuler G., and Austyn J.M. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur. J. Immunol. 30 7 (2000) 1813-1822
202. Rossner S., Voigtlander C., Wiethe C., Hanig J., Seifarth C., and Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35 12 (2005) 3533-3544
203. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J., and Penninger J.M. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 13 7 (1999) 786-791
204. Helgason C.D., Damen J.E., Rosten P., Grewal R., Sorensen P., Chappel S.M., Borowski A., Jirik F., Krystal G., and Humphries R.K. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12 11 (1998) 1610-1620
205. Ghansah T., Paraiso K.H., Highfill S., Desponts C., May S., McIntosh J.K., Wang J.W., Ninos J., Brayer J., Cheng F., Sotomayor E., and Kerr W.G. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J. Immunol. 173 12 (2004) 7324-7330
206. Paraiso K.H., Ghansah T., Costello A., Engelman R.W., and Kerr W.G. Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease. J. Immunol. 178 5 (2007) 2893-2900
207. Funeshima N., Fujino M., Kitazawa Y., Hara Y., Hara Y., Hayakawa K., Okuyama T., Kimura H., and Li X.K. Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase. J. Gene Med. 7 5 (2005) 565-575
208. Takayama T., Kaneko K., Morelli A.E., Li W., Tahara H., and Thomson A.W. Retroviral delivery of transforming growth factor-beta1 to myeloid dendritic cells: inhibition of T-cell priming ability and influence on allograft survival. Transplantation 74 1 (2002) 112-119
209. Zhang M., Wang Q., Liu Y., Sun Y., Ding G., Fu Z., Min Z., Zhu Y., and Cao X. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J. Mol. Med. 82 4 (2004) 240-249
210. Hill J.A., Ichim T.E., Kusznieruk K.P., Li M., Huang X., Yan X., Zhong R., Cairns E., Bell D.A., and Min W.P. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 171 2 (2003) 691-696
211. Li M., Zhang X., Zheng X., Lian D., Zhang Z.X., Ge W., Yang J., Vladau C., Suzuki M., Chen D., Zhong R., Garcia B., Jevnikar A.M., and Min W.P. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J. Immunol. 178 9 (2007) 5480-5487
212. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178 11 (2007) 7018-7031
213. Xu H., Chen T., Wang H.Q., Hua Y.B., and Wu W.W. Combination treatment with donor interleukin-12p35 silenced dendritic cells and cyclosporine induces long-term survival of intestinal allografts in rats. Transplant. Proc. 39 1 (2007) 286-288
214. Penna G., and Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164 5 (2000) 2405-2411
215. von Bergwelt-Baildon M.S., Popov A., Saric T., Chemnitz J., Classen S., Stoffel M.S., Fiore F., Roth U., Beyer M., Debey S., Wickenhauser C., Hanisch F.G., and Schultze J.L. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 108 1 (2006) 228-237
216. Liang S., and Horuzsko A. Mobilizing dendritic cells for tolerance by engagement of immune inhibitory receptors for HLA-G. Hum. Immunol. 64 11 (2003) 1025-1032
217. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175 9 (2005) 5601-5605
218. Loser K., Mehling A., Loeser S., Apelt J., Kuhn A., Grabbe S., Schwarz T., Penninger J.M., and Beissert S. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12 12 (2006) 1372-1379
219. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T., Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., Low W.C., Largaespada D.A., and Verfaillie C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 6893 (2002) 41-49
220. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., and Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 284 5411 (1999) 143-147
221. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 69 1 (2007) 1-9
222. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 1 (2002) 42-48
223. Eliopoulos N., Stagg J., Lejeune L., Pommey S., and Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106 13 (2005) 4057-4065
224. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza Jr. F.R., Moseley A.B., and Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 5 (2005) 389-398
225. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 9419 (2004) 1439-1441
226. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., and Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106 5 (2005) 1755-1761
227. Ishida T., Inaba M., Hisha H., Sugiura K., Adachi Y., Nagata N., Ogawa R., Good R.A., and Ikehara S. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J. Immunol. 152 6 (1994) 3119-3127
228. Augello A., Tasso R., Negrini S.M., Cancedda R., and Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis. Rheum. 56 4 (2007) 1175-1186
229. Okita K., Ichisaka T., and Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 448 7151 (2007) 313-317
230. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., Bernstein B.E., and Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448 7151 (2007) 318-324